The case for & against
Bull & Bear analysis
InMode Ltd. (NASDAQ: INMD) is a leading provider of innovative aesthetic medical technologies and minimally invasive procedures, focusing on transforming the aesthetic landscape. The company specializes in minimally invasive and non-invasive aesthetic devices that stimulate collagen and elastin, enhancing facial and body rejuvenation. With a strong position in the cosmetics market, InMode stands to benefit significantly from ongoing consumer trends towards aesthetic procedures, particularly as millions seek solutions for aesthetic concerns exacerbated by modern lifestyle factors.
Bull says
- ↑High earnings yield and strong profitability indicate efficient capital use.
- ↑Institutional ownership at ~68% signals investor confidence.
- ↑Rising demand for 'Ozempic Face' treatments expands market.
- ↑Dividend yield near 0.3% provides modest income support.
- ↑Stock crossed above its 200-day MA at $15.17, showing bullish momentum.
- ↑Manageable leverage supports financial stability.
Bear says
- ↓Flat Q2 revenue at $95.6M YoY suggests stagnant top-line growth.
- ↓Analyst revisions turning negative, indicating potential EPS downgrades.
- ↓Share-price volatility remains elevated, heightening downside risk.
- ↓Institutional buying interest is weakening, reducing stability.
- ↓Competitive pricing pressure may erode aesthetic device market share.
- ↓Demand shifts from weight-loss drugs could unpredictably impact volumes.
Investment themes with INMD
Clinical instruments and devices powering patient care
Miscellaneous or uncategorized companies
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- In addition, we're seeing early signs of stabilization, particularly in the US, and believe that this quarter reinforced our confidence that 2026 is moving in the right direction.
- reinforcing our confidence that these changes are beginning to bear fruit.
- Argentina. Argentina was established late 2025. It took us some time, two months, to get all the clearances from the regulatory body in Argentina under our name in our subsidiary. Now everything is almost ready. We have an office. We have one or two salespeople. We have a clinical trainer, we have a manager, and hopefully, Q2 in 2026, we will see some results. Until now, it was more like a setup, organizing all the regulatory clearances. Hopefully, Q2 in this year, they will start delivering cells as well. Argentina is not very big country compared to Brazil and others, but we believe that there is a market there.
Bear points
- Demand for static procedures was again pressured in the first quarter of 2026 by microeconomic headwind.
- so far, no.
- so far, no.